Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginNet MarginOperating MarginReturn on Sales

Bone Biologics (BBLG) EBITDA Margin (2016 - 2017)

Bone Biologics (BBLG) has disclosed EBITDA Margin for 2 consecutive years, with 206.36% as the latest value for Q2 2017.

  • On a quarterly basis, EBITDA Margin fell 141114.0% to 206.36% in Q2 2017 year-over-year; TTM through Dec 2017 was 152.76%, a 207599.0% decrease, with the full-year FY2025 number at 2568.41%, up 138430.0% from a year prior.
  • EBITDA Margin was 206.36% for Q2 2017 at Bone Biologics, down from 283.36% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 2936.14% in Q1 2016 to a low of 206.36% in Q2 2017.